secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0001213900-23-065674
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics updates corporate presentation; no material new information disclosed
--------------------------------------------------------------------------------

- Company filed updated corporate presentation as Exhibit 99.1 on August 10, 2023.
- Presentation titled 'Targeting Major Advances in the Treatment of CNS Disorders'.
- Filing does not include specific new financial results, guidance, or milestones.
- No material changes to corporate strategy or pipeline disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023065674/0001213900-23-065674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023065674/ea183245-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-065674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer